Advanced search
Start date
Betweenand

Glutathione depletion sensitizes cisplatin and temozolomide resistant glioma cells in vitro and in vivo

Grant number: 14/20170-0
Support type:Regular Research Grants - Publications - Scientific article
Duration: November 01, 2014 - April 30, 2015
Field of knowledge:Biological Sciences - Biochemistry
Principal Investigator:Carlos Frederico Martins Menck
Grantee:Carlos Frederico Martins Menck
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:09/52417-7 - Cell responses to genome damage, AP.TEM

Abstract

Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy. The main chemotherapy protocol for this type of tumor is based on temozolomide (TMZ), albeit with limited success. Cisplatin is widely used to treat several types of tumor and, in association with TMZ, is also used to treat recurrent glioma. However, several mechanisms of cellular resistance to cisplatin restrict therapy efficiency. In that sense, enhanced DNA repair, high glutathione levels and functional p53 have a critical role on cisplatin resistance. In this work, we explored several mechanisms of cisplatin resistance in human glioma. We showed that cellular survival was independent of the p53 status of those cells. And in a host cell reactivation assay using cisplatin-treated plasmid we did not detect any difference in DNA repair capacity. We demonstrated that, cisplatin-treated U138MG cells suffered fewer DNA double-strand breaks and DNA platination. Interestingly, the resistant cells carried higher levels of intracellular glutathione. Thus, pre-incubation with the glutathione inhibitor buthionine sulphoximine (BSO) induced massive cell death, while N-acetyl cysteine (NAC), a precursor of glutathione synthesis, improved the resistance to cisplatin treatment. In addition, BSO sensitized glioma cells to TMZ alone or in combination with cisplatin. Furthermore, using an in vivo model the combination of BSO, cisplatin and TMZ activated the caspase 3-7 apoptotic pathway. Remarkably, the combined treatment did not lead to severe side effects, while causing a huge impact on tumor progression. In fact, we noted a remarkable 3-fold increase in survival rate compared to other treatments regime. Thus, the intracellular glutathione concentration is a potential molecular marker for cisplatin resistance in glioma, and the use of glutathione inhibitors, such as BSO, in association with cisplatin and TMZ seems a promising approach for the therapy of such devastating tumors. (AU)